David Young insider trades: Processa Pharmaceuticals (PCSA) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
22 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | PCSA | ↑ Buy | 2,531 | $1.93 | $5K | Direct | Jul 1, 2026 (1d) |
| Jun 15, 2026 | PCSA | ↑ Buy | 2,067 | $2.22 | $5K | Direct | Jun 16, 2026 (1d) |
| May 15, 2026 | PCSA | ↑ Buy | 1,545 | $2.97 | $5K | Direct | May 19, 2026 (4d) |
| Apr 15, 2026 | PCSA | ↑ Buy | 1,545 | $2.97 | $5K | Direct | Apr 17, 2026 (2d) |
| Mar 31, 2026 | PCSA | ↑ Buy | 1,810 | $2.54 | $5K | Direct | Apr 1, 2026 (1d) |
| Jan 27, 2025 | PCSA | ↑ Buy | 124,500 | $0.80 | $99K | Direct | Jan 29, 2025 (2d) |
| Feb 7, 2024 | PCSA | ↑ Buy | 21,000 | $2.45 | $52K | Direct | Feb 8, 2024 (1d) |
| Feb 6, 2024 | PCSA | ↑ Buy | 20,000 | $2.53 | $51K | Direct | Feb 7, 2024 (1d) |
| Jun 12, 2023 | PCSA | ↑ Buy | 40,000 | $0.80 | $32K | Direct | Jun 12, 2023 (0d) |
| Apr 14, 2023 | PCSA | ↑ Buy | 20,000 | $0.55 | $11K | Direct | Apr 14, 2023 (0d) |
| Apr 13, 2023 | PCSA | ↑ Buy | 60,000 | $0.48 | $29K | Direct | Apr 13, 2023 (0d) |
| Jun 23, 2021 | PCSA | ↑ Buy | 10,000 | $7.67 | $77K | Direct | Jun 23, 2021 (0d) |
| Jun 24, 2014 | QCOR | ↓ Sell | 6,000 | $91.96 | $552K | Direct | Jun 26, 2014 (2d) |
| Mar 14, 2014 | QCOR | ↓ Sell | 6,000 | $62.28 | $374K | Direct | Mar 18, 2014 (4d) |
| Feb 24, 2014 | QCOR | ↓ Sell | 6,000 | $78.88 | $473K | Direct | Feb 26, 2014 (2d) |
| Jan 24, 2014 | QCOR | ↓ Sell | 6,000 | $64.38 | $386K | Direct | Jan 28, 2014 (4d) |
| Nov 13, 2013 | QCOR | ↓ Sell | 100,000 | $62.40 | $6.2M | Direct | Nov 15, 2013 (2d) |
| Apr 27, 2012 | QCOR | ↓ Sell | 70,000 | $42.81 | $3.0M | Direct | May 1, 2012 (4d) |
| Oct 31, 2011 | QCOR | ↓ Sell | 79,724 | $41.05 | $3.3M | Direct | Nov 2, 2011 (2d) |
| Aug 15, 2011 | QCOR | ↓ Sell | 15,400 | $32.00 | $493K | Direct | Aug 16, 2011 (1d) |
| Aug 5, 2011 | QCOR | ↓ Sell | 10,000 | $28.50 | $285K | Direct | Aug 9, 2011 (4d) |
| Nov 2, 2010 | QCOR | ↓ Sell | 28,125 | $12.33 | $347K | Direct | Nov 4, 2010 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other PCSA insiders
Open-market trades in the last 12 months
About David Young's insider trades
David Young is Pres. Research & Development at Processa Pharmaceuticals (PCSA). Since Nov 2, 2010, David has reported 12 open-market purchases worth $373K and 10 sales worth $15.4M on SEC Form 4. In the last 12 months: 5 buys ($23K).
Their filings also include grants and awards (28 filings), option exercises (19 filings), shares withheld for taxes (5 filings), gifts (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every PCSA insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.